Press release 📢 Announcing MMV's new partnership with South Korean biotechnology leader Shaperon to advance game-changing, nanobody treatments for #malaria prevention.

🎥 Watch the video to learn how nanobody technology can change the game for #GlobalHealth.

Vivax #malaria relapses keep patients trapped in a cycle. The Partnership for Vivax Elimination (PAVE) has been generating evidence from across endemic countries to support country elimination goals.

Paul Boateng (Ghana NMEP) on staying ahead of antimalarial drug resistance, including the use of MFT to reduce pressure on ACTs. Through the ALARM partnership, MMV & Ghana's NMEP are conducting an MFT pilot following similar successful pilots in Kenya & Burkina Faso. #WAAW25

At #CPHIA2025, Dr Edwin Onyango from Kenya’s NMCP explained partial-artemisinin resistance.

MMV & partners are developing a triple ACT, combining artemether-lumefantrine with amodiaquine. This medicine is now in Phase 3 clinical trials.

#WAAW25

What if drug resistance caused the #malaria medicines millions rely on to stop working? With signs of partial resistance emerging again, we must act now to protect the efficacy of existing tools and develop new interventions with stronger barriers to resistance. #WAAW25

Parasites developing resistance to #malaria mediciness isn’t a question of if, but when. We must act now to protect gains & secure a malaria-free future.

MMV & partners are staying one step ahead of resistance 👉 bit.ly/47MmP3x

#WAAW25

For the first time in 25 years, a new class of #malaria treatment is within reach. Today, @Novartis & MMV announce positive Phase 3 results for a novel, non-artemisinin medicine with the potential to kill drug-resistant parasites & block transmission. bit.ly/4p78R1P